Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Mirtazapine in Alzheimer-associated Weight Loss

This study has been completed.
Information provided by (Responsible Party):
Kurt Segers, Brugmann University Hospital Identifier:
First received: January 4, 2012
Last updated: January 5, 2012
Last verified: January 2012

Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect.

The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).

Condition Intervention
Alzheimer's Disease
Weight Loss
Mixed Dementia
Drug: mirtazapine

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Mirtazapine in Alzheimer-associated Weight Loss: a Retrospective Phase IV Study

Resource links provided by NLM:

Further study details as provided by Brugmann University Hospital:

Primary Outcome Measures:
  • body weight [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 22
Study Start Date: January 2004
Study Completion Date: December 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: mirtazapine
    30 mg at bedtime
    Other Name: Remergon

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients with established diagnosis of AD or mixed dementia with reported weight loss


Inclusion Criteria:

  • AD or mixed dementia
  • documented weight loss
  • mirtazapine 30 mg explicitly prescribed against weight loss

Exclusion Criteria:

  • no treatment compliance
  • other causes of weight loss
  • other interventions against weight loss
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01505504

CHU Brugmann
Brussels, Belgium, 1020
Sponsors and Collaborators
Brugmann University Hospital
  More Information

No publications provided

Responsible Party: Kurt Segers, Principal Investigator, Brugmann University Hospital Identifier: NCT01505504     History of Changes
Other Study ID Numbers: MIRTA-2012
Study First Received: January 4, 2012
Last Updated: January 5, 2012
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Additional relevant MeSH terms:
Alzheimer Disease
Body Weight
Weight Loss
Body Weight Changes
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Signs and Symptoms
Adrenergic Agents
Adrenergic Antagonists
Adrenergic alpha-Antagonists
Antidepressive Agents
Antidepressive Agents, Tricyclic
Central Nervous System Agents
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses processed this record on November 25, 2014